ArticleActa biomaterialia2026
Advanced tissue-engineered pulsatile conduit using human induced pluripotent stem cell-derived cardiomyocytes.
Article in Acta biomaterialia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Preconditioned endothelialized grafts reduce stenosis and improve vascular remodeling in a rat pulmonary artery model.Acta biomaterialia · 2026Article
- Human-Induced Pluripotent Stem Cell Models for Amyloid Cardiomyopathy: From Mechanistic Insights to Therapeutic Discovery.Journal of cardiovascular development and disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Single ventricle congenital heart defects (SVCHDs) are life-threatening defects that can lead to severe circulation issues and increased stress on the heart. Without prompt treatment, these defects can prove fatal in infancy. Fontan surgery is a conventional treatment for SVCHDs, which reroutes oxygen-poor blood directly to the lungs, bypassing the non-functioning ventricle. This procedure, however, can lead to circulation inefficiencies due to the absence of a natural, functional ventricle to pump blood to the pulmonary circulation. To address this issue, our team previously developed a tissue-engineered pulsatile conduit (TEPC) by wrapping engineered heart tissues (EHTs) derived from human induced pluripotent stem cell-derived cardiomyocytes (hiPSCCMs) around decellularized human umbilical artery (dHUA). This conduit has demonstrated the ability to produce a luminal pressure of 0.68 mmHg from spontaneous beating, which under 2 Hz electrical stimulation, increases to 0.83 mmHg. This offers a promising modular TEPC design that has the potential to provide active pumping function to the pulmonary circulation. We have since significantly optimized our approach by providing the conduit with electrical pacing training and an additional layer of EHT. These two enhancements have achieved markedly greater contractile productivity, where the spontaneous pressure generation reached 0.96 mmHg and the stimulated luminal pressure generation attained 1.87 mmHg with 2 Hz pacing. Our studies thus underscore the effectiveness of these TEPC design modifications, marking significant progress in the ongoing effort to improve treatments for patients with SVCHDs. STATEMENT OF SIGNIFICANCE: Single ventricle congenital heart defects (SVCHDs) are a life-threatening disorder, leading to severe circulation issues and heart failure. The Fontan procedure reroutes blood to the lung but lacks active pumping required for efficient circulation, often causing long-term complications. To address this challenge, we developed a tissue-engineered pulsatile conduit (TEPC) using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and decellularized human umbilical artery (dHUA) scaffolds. Our optimized design, with electrical pacing and enhanced engineered heart tissue (EHT) approaches, significantly increased luminal pressure development (up to 1.87 mmHg at 2 Hz frequency), offering a promising solution to improve outcomes for SVCHD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.